News

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending April 17, 2020.

Data out to 11 years suggest that individualized doses of brivaracetam (Briviact; UCB Pharma) are safe and effective in reducing focal and primary generalized seizures.

"Mind Moments," a podcast from NeurologyLive, brings you an exclusive interview with Fernando Pagan, MD.

The professor of neurology at the University of Vermont Larner College of Medicine and founding president of the Alliance for Headache Disorders Advocacy discussed the special article he and colleagues published in the Headache journal on migraine care.

Stroke care, including acute treatment and prevention, faces unique challenges in rural areas where disease awareness is lacking and access to high-level care in scarce.

Consumption of whole fruits, vegetables, whole grains, nuts, legumes, fish and olive oil, as well as reduced consumption of red meat and alcohol was observed to assist in preserving cognitive function.

In those with secondary progressive MS, evaluating diffusely abnormal white matter may provide a useful measure for therapies aiming to protect at-risk tissue, which may be able to slow progression.

The chief medical advisor for the Muscular Dystrophy Association discussed how the ongoing novel coronavirus pandemic will have a lasting impact on the use of telemedicine in the neuromuscular community­­.

Migraine expert Teshamae Monteith, MD, describes how the University of Miami's inpatient migraine service has been a go-to resource for migraine help.

Elevated risk of falling, an indicator of early stage Parkinson Diseas, could be predicted by a simple tandem gait test.

Leaders from the University of Miami Miller School of Medicine detail the most important needs in the field of stroke and steps needed to take in 2020.

The Processing Speed Test, a tech-enabled version of the SDMT, was shown to be significantly correlated with multiple measures in routine multiple sclerosis care.

The CEO of Biohaven Pharmaceuticals discussed the company’s new collaboration, which has made rimegepant (Nurtec ODT) available for prescription through Cove’s telemedicine platform.

The director of the Multiple Sclerosis Program at Cleveland Clinic Lou Ruvo Center for Brain Health discussed the correlation between age and disease duration in MS, as well as what was learned from a subanalysis of the EXPAND study of siponimod.

The professor of neurology at the University of Vermont Larner College of Medicine and founding president of the Alliance for Headache Disorders Advocacy discussed the need to get patients with migraine access to medications during the COVID-19 pandemic.

The Director of the Sleep Disorders Center and vice chair of the department of neurology at UCLA David Geffen School of Medicine describes why labeling patients can lead to a misdiagnosis of narcolepsy.

Biohaven Pharmaceutical’s oral acute migraine agent rimegepant (Nurtec ODT) is the first branded medication available through Cove’s platform, which provides consults with independent health care providers and access to prescriptions.

In addition to having a lowered number of headache days, around 20% of patients transformed to low-frequency, episodic migraine on follow-up.

The professor of neurology at the University of Vermont Larner College of Medicine and founding president of the Alliance for Headache Disorders Advocacy spoke about the impact the COVID-19 pandemic has had on his practice.

Selumetinib becomes the first therapy approved for pediatric patients with Neurofibromatosis type 1.

Incorporating remote electrical neuromodulation into the standard of care may have a positive impact on migraine management by reducing the reliance on acute medications.

The probability of relapse and disability progression during pregnancy was associated with time when natalizumab was stopped and number of relapses in the year before natalizumab treatment.

The drug successfully demonstrated an ability to reduce mutant huntingtin protein, but the clinical benefits of that effect are yet to be determined.

Examining the underlying roles of poly adenosine diphosphate-ribose (PARP) play in the neurodegeneration of Parkinson disease.

The assistant professor of Neurology, Concussion and Headache Medicine divisions, Mayo Clinic, Scottsdale, Arizona discussed the evolving migraine treatment landscape and how they have been incorporated into her practice.

Neurology News Network for the week ending April 11, 2020.

Results from one of the first multi-case studies of neurologic manifestations of COVID-19 demonstrate complex CNS involvement and raise further questions about pathological mechanism.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending April 10, 2020.